Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label study without randomisation. All eligible patients will receive two
administrations of the investigational imaging agent [18F]PI-2620 at a radioactive dose of
185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low
specific activity (40-50 µg tracer mass dose).